A Polypill for Acute Coronary Syndrome
Recruiting now · Phase 2
Conditions studied: Acute Coronary Syndrome
In brief
The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.
Key facts
- Study ID
- NCT07032389
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 1000
- Starts
- 2025-12-05
- Expected to finish
- 2030-07-31
- Last updated by the study team
- 2026-07-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18
- Hospitalization for acute coronary syndrome with percutaneous coronary intervention
- Discharged on aspirin, prasugrel or clopidogrel, and a high-intensity statin
You may not qualify if…
- Current need for systemic anticoagulation
- Contraindication to receive any components of the polypill
- History of allergic reaction or intolerance to aspirin, prasugrel or clopidogrel, or rosuvastatin
- Comorbidities that might be expected to limit lifespan within the 12-month study period
- Increased risk of bleeding or planned urgent surgery that would necessitate use of DAPT for < 12 months
- Inability to provide written informed consent
- Pregnancy
Where it is running
- Baylor Scott and White Health System — Dallas, Texas, United States (enrolling)
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.